Clinical Trial Report Week 2nd - 6th March 2020

Thirteen Companies Reported Headline Results in Advancing their Candidate Product Through Clinical Trials

Like many aspects of healthcare business space, drug development is in a state of constant change for the purpose of better health outcomes. A summarised report of new drug therapies in clinical trials worldwide during the week 2 - 6 March 2020 is presented. Secondary research findings from investment and business reports are tabulated by the sponsor, whether the study is at phase I, II or III of the clinical trial, the drug candidate name or code, clinical indication, the status of the study investigation in terms of study design and patient recruitment and any other significant comment(s) about the clinical study.

The purpose of this report is to present accurate and timely information on clinical trials worldwide, in the anticipation that resources for future clinical trials may be better allocated and development costs lowered. All content given in this report is for informational purposes only and does not constitute patient, clinical or financial advice.

Products Mentioned:

• MTL-CEBPA
• ONCOS-102
• KEYTRUDA®
• HBI-3000
• DYN101
• AGN-151587 (EDIT-101)
• ARO-HSD
• IDCT
• OP0201
• VBI-1901
• GM-CSF
• AS01B
• IBI375 (Pemigatinib)
• NLY01
• mRNA-1647
• ABV-1505